Valneva SE (NASDAQ:VALN – Free Report) – Stock analysts at HC Wainwright increased their Q3 2024 EPS estimates for Valneva in a research report issued on Wednesday, September 25th. HC Wainwright analyst E. White now expects that the company will earn ($0.29) per share for the quarter, up from their previous estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Valneva’s Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.38) EPS.
Valneva Stock Performance
VALN stock opened at $6.21 on Friday. The firm has a market cap of $432.46 million, a price-to-earnings ratio of -15.15 and a beta of 2.19. The firm has a 50-day simple moving average of $7.06 and a two-hundred day simple moving average of $7.57. Valneva has a one year low of $5.70 and a one year high of $14.49. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.15 and a current ratio of 2.63.
Hedge Funds Weigh In On Valneva
An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its stake in Valneva SE (NASDAQ:VALN – Free Report) by 42.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 88,252 shares of the company’s stock after purchasing an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.39% of the company’s stock.
Valneva Company Profile
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Articles
- Five stocks we like better than Valneva
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Breakout Stocks: What They Are and How to Identify Them
- MarketBeat Week in Review – 9/23 – 9/27
- With Risk Tolerance, One Size Does Not Fit All
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.